Table 2.
Target enrichment.
| Cancer type | Eligible miRNAsa | Significant miRNAsb (%) |
|---|---|---|
| ACC | 4 | 0 |
| BLCA | 6 | 67 |
| BRCA | 59 | 63 |
| CESC | 8 | 88 |
| DLBC | 6 | 83 |
| ESCA | 5 | 60 |
| HNSC | 3 | 67 |
| KIRC | 3 | 67 |
| LAML | 7 | 43 |
| LGG | 2 | 100 |
| LIHC | 7 | 43 |
| LUAD | 4 | 50 |
| LUSC | 3 | 100 |
| OV | 27 | 89 |
| PAAD | 7 | 57 |
| PRAD | 1 | 100 |
| THCA | 1 | 0 |
| UCEC | 11 | 55 |
For fourteen different cancer types, at least 50% of the "Eligible miRNAs" had significantly enriched computed targets in the ground truth data (p-value < 0.05).
aNo. of "Eligible miRNAs" for hypergeometric test for the enrichment of known targets; bpercentage of miRNAs with hypergeometric p-values < 0.05.